Supplementary Figure 1 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure 1. Differentially expressed genes (Left) and gene signatures (Right) Cisplatin-Olaparib (A, B), Olaparib (C,D) and Durvalumab-Olaparib (E, F) arms in pre- and post-treatment samples. The significance (p-value, P and adjusted p-value, Padj) is represented relative to Fold Change (FC) in the x-axis.
Authors: Myrto Moutafi, Georgia-Angeliki Koliou, George Papaxoinis, Panagiota Economopoulou, Ioannis Kotsantis, Maria Gkotzamanidou, Maria Anastasiou, Dimitrios Pectasides, Efthymios Kyrodimos, Alexander Delides, Evangelos Giotakis, Nikolaos G. Papadimitriou, Ioannis G. Panayiotides, Christos Perisanidis, Aileen I. Fernandez, Vasiliki Xirou, Christos Poulios, Eleni Gagari, Vesal Yaghoobi, Niki Gavrielatou, Saba Shafi, Thazin Nwe Aung, Andromachi Kougioumtzopoulou, Vassilis Kouloulias, Konstantinos Palialexis, Stavros Gkolfinopoulos, Areti Strati, Evi Lianidou, George Fountzilas, David L. Rimm, Periklis G. Foukas, Amanda Psyrri
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4384522806